Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Cerebrale hemodynamische optimalisatie door milrinon om vertraagde cerebrale ischemie te voorkomen (OPTIMIL)

4 november 2026 bijgewerkt door: University Hospital, Toulouse

Efficacy of 10 Days Intravenous Milrinone Treatment to Optimize Cerebral Hemodynamic and Prevent Delayed Cerebral Ischemia (DCI) in Patients With Severe Subarachnoid Hemorrhage Due to Intracranial Aneurysm Rupture

The present study is a randomized, multi-center, double-blind, prospective study that tests the efficacy of intravenous milrinone to optimize cerebral hemodynamic and prevent delayed cerebral ischemia (DCI) during the high-risk period (day 4- day 14) in patients with severe subarachnoid hemorrhage due to intracranial aneurysm rupture (SAHa) (WFNS IV-V). The main objective is to evaluate, in comatose patients and / or sedated on D3 following a severe SAHa (WFNS IV -V), the effect of 10 days of milrinone versus placebo, in addition to the usual management, on the volume of DCI lesions measured on CT scan at 1 month.

Studie Overzicht

Toestand

Actief, niet wervend

Gedetailleerde beschrijving

After SAHa, approximately 28% of patients will present DCI. DCI is a major cause of death and disability and will condition the neurological prognosis. Its treatment is not really codified, because of the absence of scientific proof of good level. Milrinone, an inhibitor of type III phosphodiesterase, seems particularly interesting in the management of DCI. This molecule has indeed a powerful vasodilator action. In addition, its anti-inflammatory effects could inhibit the abnormal proliferation of vascular smooth muscle cells and the remodelling observed in patients with DCI via an action on interleukin-6. Finally, because of its positive inotropic effect, it is an interesting choice in these patients with neurogenic cardiomyopathy where the administration of catecholamines is to be avoided. Strong evidence for efficacy of milrinone in the treatment and / or prevention of DCI is still lacking. All patients will benefit from a computed tomography (CT) brain imaging at 48 hrs following aneurysm treatment to define baseline imaging. The standard care (SC) group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from day 4 to day 14. The milrinone (M) group will receive, in addition to standard care, administration of milrinone (0.75 μg / kg / min, intravenous) from day 4 to day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From day 4 to day 14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.

Studietype

Ingrijpend

Inschrijving (Geschat)

234

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Bordeaux, Frankrijk
        • University Hospital Bordeaux
      • Grenoble, Frankrijk
        • CHUGA
      • La Réunion, Frankrijk
        • University Hospital of La Réunion
      • Lyon, Frankrijk
        • HCL
      • Toulouse, Frankrijk
        • University Hospital of Toulouse

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • patients with severe SAHa (WFNS IV and V,) whose neurological examination is impossible because of coma (Glasgow coma score of 8 or less) or need for sedation at D3
  • absence of pre-existing neurological handicap (mRS 0-2)
  • major patient (≥ 18 years)
  • affiliation to social security or benefiting through a third person
  • free patient, without tutorship or curatorship or under judicial protection
  • obtaining a signed informed consent by a relative (or the person of trust) after clear and fair information about the study.

Exclusion Criteria:

  • patients with non-severe SAHa (WFNS I, II and III)
  • Occurrence of a major complication (haemorrhagic or ischaemic) documented during the procedure of securing the aneurysm and endangering the short-term vital prognosis
  • heart failure requiring inotropic administration at the time of randomization
  • ICHT at the time of randomisation (ICP> 25 mmHg for at least 20 min)
  • known severe obstructive heart diseases
  • flutter patient or atrial fibrillation
  • hypotension and / or severe hypovolemia with hemodynamic instability
  • septic shock
  • acute / chronic renal insufficiency (Cl <50ml / min)
  • major hydroelectrolytic disorders (hypokalemia <3 mmol / L)
  • known hypersensitivity to milrinone or any of the excipients
  • early limitation of life-sustaining care
  • pregnancy, breastfeeding
  • permanent contraindications to MRI
  • participation in another clinical interventional study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Milrinone

"milrinone" group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.

administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14

Placebo-vergelijker: Standard Care

The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.

administration of placebo (intravenous glucose 5%) from Day 4 to Day 14

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
volume of delayed cerebral ischemia lesions
Tijdsspanne: 1 month

volume of DCI lesions measured on CT scan and validated by Magnetic Resonance Imaging (MRI) imaging at 1 month

1 month

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Radiological parameters on CT at 1 month
Tijdsspanne: 1 month

percentage of patients with DCI lesions

1 month
Evolution in intensive care: Neurological complications 1
Tijdsspanne: 1 month

number of episodes of PtiO2 below the ischemic threshold in intensive care: PtiO2 <20 mmHg (moderate hypoxia) and <15 mm Hg (severe hypoxia) for at least 15 minutes

1 month
Evolution in intensive care: Neurological complications 2
Tijdsspanne: 1 month

total duration of episodes of PtiO2 <20 mm Hg (moderate hypoxia) and <15 mm Hg (severe hypoxia)

1 month
Evolution in intensive care: Neurological complications 3
Tijdsspanne: 1 month

number of recourse to an endovascular treatment

1 month
Evolution in intensive care: Neurological complications 4
Tijdsspanne: 1 month

intracranial hypertension in intensive care: ICP> 20 mmHg for at least 15 minutes.

1 month
Number and type of non-neurological complications
Tijdsspanne: 1 month

non-neurological complications

1 month
Number of days in intensive care
Tijdsspanne: 1 month

Number of days in intensive care

1 month
Number of days with mechanical ventilation
Tijdsspanne: 1 month

Number of days with mechanical ventilation

1 month
neurological prognosis at 1 month: Rankin score
Tijdsspanne: 1 month

evaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)

1 month
neurological prognosis at 1 month: Glasgow Outcome scale
Tijdsspanne: 1 month

evaluated by the Glasgow Outcome Scale (GOS) (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3).

1 month
neurological prognosis at 3 month: Rankin score
Tijdsspanne: 3 month

evaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)

3 month
neurological prognosis at 3 month: Glasgow Outcome scale
Tijdsspanne: 3 month

evaluated by the the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)

3 month
neurological prognosis at 6 month: Rankin score
Tijdsspanne: 6 month

evaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)

6 month
neurological prognosis at 6 month: Glasgow Outcome scale
Tijdsspanne: 6 month

evaluated by the the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)

6 month
neurological prognosis at 1 year: Rankin score
Tijdsspanne: 1 year

evaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)

1 year
neurological prognosis at 1 year: Glasgow Outcome scale
Tijdsspanne: 1 year

evaluated by the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)

1 year
Mortality at 1 month
Tijdsspanne: 1 month

Mortality at 1 month

1 month
Mortality at 3 month
Tijdsspanne: 3 month

Mortality at 3 month

3 month
Mortality at 6 month
Tijdsspanne: 6 month

Mortality at 6 month

6 month
Mortality at 1 year
Tijdsspanne: 1 year

Mortality at 1 year

1 year
number of days of hospitalization
Tijdsspanne: 1 year

number of days of hospitalization

1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Thomas Geeraerts, MD PhD, University Hospital, Toulouse

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 juli 2021

Primaire voltooiing (Geschat)

1 juli 2027

Studie voltooiing (Geschat)

1 juli 2027

Studieregistratiedata

Eerst ingediend

17 februari 2020

Eerst ingediend dat voldeed aan de QC-criteria

20 februari 2020

Eerst geplaatst (Werkelijk)

25 februari 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren